

MO HEALTHNET DRUG UTILIZATION REVIEW BOARD

July 18, 2018

Missouri Coalition for Community Behavioral Healthcare, 221 Metro Dr., Lower Level CEO Room, Jefferson City MO

DUR BOARD MEMBERS PRESENT

Ginger Nicol, MD, CEDS, Filled in for Board Chair
Charlene Heyde, RPh
Randy Beckner, Pharm D
Glen Talboy, MD
Sandra Bollinger, Pharm D
Kenneth Haller, MD
Jennifer Passanise, FNP

MHD STAFF PRESENT

Mark Roaseau, R.Ph, Clinical Pharmacist
Angela Wilson, Pharmacy Operations Manager
Frances (Franki) Moseley, Administrative Office Support Assistant
Elizabeth Sissom, RN, Clinical Management
Lisa Smith, Program Development Specialist
Mitch Ruth, Pharmacy Fiscal Unit Manager
Sharie Hahn, Special Council
Dr. Timothy Kling, MD, Assistant Medical Director

DUR BOARD MEMBERS ABSENT

Susan Abdel-Rahman, Pharm D – Board Chair
Stacy Mangum, Pharm D

CONTRACTED STAFF PRESENT

Joshua Moore, Pharm D, Conduent
Katie Wilbers, Pharm D, Conduent
Luke Boehmer, Pharm D, Conduent
Janelle Sheen, Pharm D, Conduent
Richard Pope, Pharm D, Magellan
Chelsea Pendleton, Wipro
Geri Roling, Wipro

OTHERS IN ATTENDANCE

Mike Lafond, AbbVie
Ashley Polce, AbbVie
Evan Rushing, Alkermes
Rob Kilo, Biogen
Tami Sova, Biogen
Tom Guyer, Eli Lilly
Jennifer Davis, Kite
Donald Kempin, Novo Nordisk

Marla Wiedermann, Novo Nordisk
Terry McCurren, Otsuka
Jim Bauman, Pfizer
Phillip King, Pfizer
Jeff Knappen, Spark
Rei Nakamara, Spark
Louis Konneman, St. Louis College of Pharmacy Student
Daniel Krolak SIUE Student

Eric Gardner, Vertex Pharma
Heather Maruska, United Healthcare
Mike Holmes, Sunovion

Welcome, Introductions and Opening Remarks	Ginger Nicol, MD, CEDS, called the meeting to order. Mark Roaseau, RPh, facilitated the meeting on behalf of the MO HealthNet Division (MHD). Introductions were made all around.
Minutes Review and Approval	Minutes of the April 2018 DUR Board meeting were reviewed and approved as submitted. (See Roll Call Votes)
Pharmacy Program/Budget Update	Mitch Ruth, Pharmacy Fiscal Unit Manager, presented a brief power point presentation. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking and State Opioid activities.
Old Business Implementation Schedule	Mark Roaseau discussed the Proposed Implementation Schedule for Edits, including PDL classes being presented for annual review, which was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included March/April, 2018 PDL decisions to be implemented July 2018. Pending ratification, PDL decisions from the June 2018 Drug PA Committee meeting will be implemented October 2018. Schedules may be found on the MHD web page at https://dss.mo.gov/mhd/cs/pharmacy/pdf/impsched.pdf
New Drug Review	Mark Roaseau reviewed the new drug products identified for the quarter January, February, March, 2018 and the recommended status within the clinical program. <ul style="list-style-type: none"> • Discussion - A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet, along with the Drug Prior Authorization Committee's actions/decisions. This listing was also provided to all attending.
Clinical Edits	
Gene Therapy Clinical Edit - Luxturna	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau reviewed the criteria in this new document including the approval and denial criteria. • Public Hearing – Rei Nakamura, Spark TX, commented on Luxturna. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)
Mepsevii Clinical Edit	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau reviewed the criteria in this new document including the approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)

Cystic Fibrosis Transmembrane Conductance Regulator Corrector/Potentiator Clinical Edit – Kalydeco, Orkambi and Symdeko	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau reviewed the criteria in this new document including the approval and denial criteria. ● Public Hearing – No comments entered. ● Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)
CAR T Cell Therapy Clinical Edit – Kymriah and Yescarta	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau reviewed the criteria in this new document including the approval and denial criteria. ● Public Hearing – No comments entered. ● Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)

Preferred Drug List (PDL)	
Amylin Analogs	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Antihyperuricemic Agents	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Bile Salts Agents	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Bone Deossification Suppression Agents	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
BPH Agents	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. Randy Beckner abstained. (See Roll Call Votes)
Cephalosporins and Related Antibiotics - Oral	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).

Cryopyrin-Associated Periodic Syndrome (CAPS)	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes)
DPP-IV (Dipeptidyl Peptidase-4) Inhibitors	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Electrolyte Depletors	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes)
Fluoroquinolones – Oral	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
GI Antibiotics – Oral:	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
GLP-1 Receptor Agonists (Anti-Diabetic Mimetics)	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes)
Growth Hormones and Growth Factors	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Hematopoietic Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Hepatitis C Therapy	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Insulins	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Insulins – Long Acting	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents • Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).

Insulins – Mix	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Insulins – Rapid Acting	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Intravaginal Antibiotics	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was discussed and on the Preferred Agents, Clindamycin Vaginal Cream was to be removed and Clindesse was to be added. These changes were accepted and added to the block vote. (See Roll Call Votes).
Macrolides – Adult	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Macrolides – Pediatric	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Methotrexate Products – Oral and Injectable	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Multiple Sclerosis (MS) Agents	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Oral Anti-Diabetics: Alpha-Glucosidase Inhibitors	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Oral Anti-Diabetics: Biguanides	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Oral Anti-Diabetics: Combinations	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Oral Anti-Diabetics: Meglitinides	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Oral Anti-Diabetics: Sulfonylureas 2nd Gen	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).

Oral Anti-Diabetics: Thiazolidinediones	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Penicillins	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Sodium-Glucose Co-Transporter 2 (SGLT2)	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Targeted Immune Modulators	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. It was pointed out that several products had new FDA approved indications that were missing from the edit. They were: Cimzia – psoriasis; Taltz – psoriatic arthritis; Xeljanz and Xeljanz XR – psoriatic arthritis and ulcerative colitis ● Decision – The board voted to include the new indications as noted. The edit with additional indications was added to the block vote. (See Roll Call Votes).
Tetracyclines	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Urinary Tract Antispasmodics	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Updates on the Antipsycotics – 2nd Generation (Atypical) and ADHD Therapy PDL’s	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau discussed that a new PDL class, 2nd Generation Antipsychotics (Atypical), was to have been presented to the Drug Prior Authorization Committee however MO HealthNet chose to table the presenting of the PDL edit but allowed public comment. Another new PDL Class, ADHD, was presented and at the request of the committee tabled the presentation to allow additional input to be considered. It was also announced that there has been a change in MO HealthNet’s PDL vendor. The new vendor is Conduent. Conduent will be responsible for solicitation of supplemental rebates going forward.
Call Center Statistics Clinical Edit Summary Report	A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were shared. Luke Boehmer reviewed how many sites/physical locations are trained and have access to Cyber Access. Reports also detailed the number and type of prescribers and active users on Cyber Access.
Conduent Update	Luke Boehmer, Pharm D, presented the following items for review. The Call Center Statistics, Claims, Spend, and Diagnosis information for the SSRI’s and SNRI’s. Dr. Boehmer also presented an updated analysis of the Opioid

	Edits that included the distinct members over 90 MME and also the number of opioid naïve participants that we currently have over 50 MME without a PA. Lastly, Dr. Boehmer presented the New Drug Summary,
Preferred Drug List Announcement	A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. There was a verbal add in of ADHD that was agreed upon by the board. This handout was also provided to all attendees and will be posted to the Division's web page: http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf
Program Utilization: Top 25 Drugs Summary	Luke Boehmer, Pharm D, reviewed the Top 25 Drugs Summary Reports for the 1st, 2 nd , 3 rd , & 4th quarter 2017. It was noticed that our reports in the packets were incorrect and the board will be emailed the correct ones for future review. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims.
Adjourn	Sandra Bollinger made a motion to move to close the meeting under Section 610.021 (5), (14) to go into Executive Session for the sole purpose of discussing individual participant specific medical information. (See attached roll call vote). At the conclusion of this discussion the meeting was adjourned entertaining no further business, actions, or motions. (See attached roll call vote). The next DUR Board meeting is scheduled for October 17, 2018, at the Missouri Coalition for Community Behavioral Healthcare, Lower Level CEO Room, 221 Metro Drive , Jefferson City MO.

Roll Call Votes – July 18, 2018

MEMBERS	MEETING MINUTES	ALL RECOMMENDATIONS BLOCK VOTE	CLOSED SESSION PURSUANT TO SECTION 610.021 SUBSECTION (14), (5)	ADJOURN EXECUTIVE SESSION
Susan Abdel-Rahman, Pharm D	A	A	A	
Charlene Heyde, RPh	S, Y	Y	Y	
Sandra Bollinger, Pharm D	M, Y	M, Y	Y	
Kenneth Haller, MD	Y	Y	M, Y	
Glenn Talboy, MD	Y	Y	Y	
Jennifer Passanise, FNP	Y	S, Y	Y	
Stacy Mangum, Pharm D				
Ginger Nicol, MD, CEDS	Y	Y	Y	

Randy Beckner, Pharm D	Y	Y	S, Y	
------------------------	---	---	------	--

(Randy Beckner abstained on BPH Agents)

- M - Motion to vote**
- S - Second to vote**
- Y - Yes to the vote**
- N - No to the vote**
- A - Absent**
- AB - Abstain vote**

EXECUTIVE SESSION
July 18, 2018

DUR BOARD MEMBERS PRESENT

Ginger Nicol, MD, CEDS-filled in as Board Chair
Charlene Heyde, RPh
Sandra Bollinger, Pharm D
Randy Beckner, Pharm D
Glen Talboy, MD
Kenneth Haller, MD
Jennifer Passanise, FNP

DUR BOARD MEMBERS ABSENT

Susan Abdel-Rahman, Pharm D – Board Chair
Stacy Mangum, Pharm D

MHD STAFF PRESENT

Mark Roaseau, RPh, Clinical Pharmacist
Sharie Hahn, Special Council
Angela Wilson, Program Developmental Specialist
Elizabeth Sissom, RN, Clinical Management
Lisa Smith, Program Development Specialist
Mitch Ruth, Pharmacy Fiscal Unit Manager
Frances (Franki) Moseley, Administrative Office Support Assistant
Dr. Timothy Kling, MD, Assistant Medical Director

CONTRACTED STAFF PRESENT

Joshua Moore, Pharm D, Conduent
Katie Wilburs, Pharm D, Conduent
Luke Boehmer, Pharm D, Conduent
Janelle Sheen, Pharm D, Conduent
Chelsea Pendleton, Wipro

Minutes Review	There were no January minutes for the Executive Session to be approved as submitted.
Case Reviews	No Case for Review
Adjourn	Executive session